TISCH CANCER INSTITUTE AT THE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI Principal Investigator/Director: Ramon Parsons, MD, PhD ABSTRACT: The mission of the Tisch Cancer Institute is to advance basic, clinical and population health cancer research, so as to prevent cancer in healthy individuals and improve the lives of cancer patients and their families in our diverse communities. To accomplish this mission, the TCI has developed collaborative research programs that strive to translate discoveries to new therapies and to develop new prevention and delivery strategies with priority given to cancers affecting our catchment area. TCI?s four cancer research programs are: Cancer Immunology, Cancer Mechanisms, Cancer Prevention and Control, and Cancer Clinical Investigation. Within its four programs, the TCI has a strong foundation of cancer research with direct cancer-related funding of $53,106,982. This includes peer-reviewed funding of $36,910,750, of which $27,662,959 is NIH funding, including $15,939,357 from the NCI. The TCI fosters intra and inter-programmatic cancer research through strategic planning, pilot project awards, interdisciplinary meetings and retreats, and disease-specific focus groups. In addition, the TCI enables cutting-edge research by providing outstanding cores, equipment, facilities and information technology. TCI supports the following five shared resources: Flow Cytometry, Mouse Genetics, Microscopy, Biostatistics, and Human Immune Monitoring Center, as well as the following three cores-in- development: Biorepository and Pathology Core, Bioinformatics for Next Generation Sequencing, and Biomedical Data Science and Informatics. The Cancer Clinical Trials Office with its newly established Early Phase Trials Unit provides the infrastructure to conduct novel, investigator initiated protocols developed by TCI investigators. The TCI?s catchment area includes the New York City (NYC) neighborhoods of East Harlem, Central Harlem and the Upper East Side, with the Harlems experiencing excess cancer incidence, morbidity and mortality as compared to NYC and the US. In addition, the TCI is the coordinating center for the World Trade Center First Responders Program, and the rescue workers affected by the 9/11 attacks form a distinct and unique component of the TCI catchment area. TCI develops and fosters a dynamic team of scientists, clinical investigators and administrators and provides the research infrastructure support needed to spur new cancer discoveries and improve the outcomes of cancer patients and their families.

Public Health Relevance

TISCH CANCER INSTITUTE AT THE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI Principal Investigator/Director: Ramon Parsons, MD, PhD Public Health Relevance Statement: The Tisch Cancer Institute provides an infrastructure to advance basic, clinical and population health cancer research, so as to prevent cancer in healthy individuals and improve the lives of cancer patients and their families in our diverse communities. To accomplish this mission, the TCI has developed collaborative research programs that strive to translate discoveries to new therapies and to develop new prevention and delivery strategies with priority given to cancers affecting our catchment area. The Cancer Clinical Trials Office with its newly established Early Phase Trials Unit provides the infrastructure to conduct novel, investigator initiated protocols developed by TCI investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA196521-06
Application #
10022654
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
2015-08-01
Project End
2025-07-31
Budget Start
2020-08-11
Budget End
2021-07-31
Support Year
6
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Icahn School of Medicine at Mount Sinai
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Galsky, Matthew D; Wang, Huan; Hahn, Noah M et al. (2018) Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. Eur Urol 73:751-759
Tsuchida, Takuma; Lee, Youngmin A; Fujiwara, Naoto et al. (2018) A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. J Hepatol 69:385-395
Molotkov, Andrei; Soriano, Philippe (2018) Distinct mechanisms for PDGF and FGF signaling in primitive endoderm development. Dev Biol 442:155-161
Wu, Vernon; Moshier, Erin; Leng, Siyang et al. (2018) Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling. Blood Adv 2:1470-1479
Parua, Pabitra K; Booth, Gregory T; Sansó, Miriam et al. (2018) A Cdk9-PP1 switch regulates the elongation-termination transition of RNA polymerase II. Nature 558:460-464
Zhang, Yan M; Zimmer, Milena A; Guardia, Talia et al. (2018) Distant Insulin Signaling Regulates Vertebrate Pigmentation through the Sheddase Bace2. Dev Cell 45:580-594.e7
Schwartz, Rebecca M; Gorbenko, Ksenia; Kerath, Samantha M et al. (2018) Thoracic surgeon and patient focus groups on decision-making in early-stage lung cancer surgery. Future Oncol 14:151-163
Lee, Youngmin A; Noon, Luke A; Akat, Kemal M et al. (2018) Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap. Nat Commun 9:4962
Laganà, A; Perumal, D; Melnekoff, D et al. (2018) Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma. Leukemia 32:120-130
Scarborough, Bethann M; Smith, Cardinale B (2018) Optimal pain management for patients with cancer in the modern era. CA Cancer J Clin 68:182-196

Showing the most recent 10 out of 143 publications